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Nuclear export signalIn this study we examined the transport signals contributing to HPV16 L2 nucleocytoplasmic trafﬁc using
confocal microscopy analysis of enhanced green ﬂuorescent protein—L2 (EGFP-L2) fusions expressed in
HeLa cells. We conﬁrmed that both nuclear localization signals (NLSs), the nNLS (1MRHKRSAKRTKR12)
and cNLS (456RKRRKR461), previously characterized in vitro (Darshan et al., 2004), function independently
in vivo. We discovered that a middle region rich in arginine residues (296SRRTGIRYSRIGNKQTLRTRS316)
functions as a nuclear retention sequence (NRS), as mutagenesis of critical arginine residues within
this NRS reduced the fraction of L2 in the nucleus despite the presence of both NLSs. Signiﬁcantly, the infec-
tivity of HPV16 pseudoviruses containing either RR297AA or RR297EE within the L2 NRS was strongly re-
duced both in HaCaT cells and in a murine challenge model. Experiments using Ratjadone A nuclear export
inhibitor and mutation-localization analysis lead to the discovery of a leucine-rich nuclear export signal
(462LPYFFSDVSL) mediating 16L2 nuclear export. These data indicate that HPV16 L2 nucleocytoplasmic trafﬁc
is dependent on multiple functional transport signals.
© 2011 Elsevier Inc. All rights reserved.Introduction
Human papillomavirus (HPV) infection is associated with more
than 99% of cervical cancers, and approximately 500,000 new cases
of cervical cancer are diagnosed each year with the mean age for de-
velopment of malignancy being 52 years. In addition, a high percent
of anal, perianal, vulvar, penile, oropharyngeal and non-melanoma
skin cancers are linked to HPV infections. Some 30 distinct HPV geno-
types are preferentially infecting anogenital mucosal epithelial
tissues. Mucosal HPVs have demonstrated varying degrees of onco-
genic potential, with some classiﬁed as high risk, such as types 16,
18, 31 and 45, and others as low risk, such as types 6 and 11. High
risk HPVs are frequently detected in invasive cervical carcinomas,
whereas the low risk types are more often associated with benign
exophytic condylomas (Longworth and Laimins, 2004; zur Hausen,
2009).
HPVs are small, non-enveloped, icosahedral DNA viruses
(55–60 nm in diameter) consisting of a single molecule of 8 kb
double-stranded circular DNA contained within a icosahedral capsidclear localization signal; NES,
EGFP, enhanced green ﬂuores-
epartment, Higgins Hall, room
7, USA. Fax:+1 617 552 2011.
rights reserved.composed of 72L1 homopentamers (capsomers). The L2 minor capsid
protein is present in up to 72 copies per virion, most likely one L2
molecule in the center of each L1 capsomer (Buck et al., 2008). Al-
though several aspects of the viral life cycle can occur in organotypic
raft culture in the absence of L2 protein, virion progeny encapsidated
10-fold less viral DNA and there was an over 100-fold reduction in
infectivity. These data suggest that L2 plays additional role(s) in the
viral life cycle distinct from genome encapsidation (Holmgren et al.,
2005). Indeed there is evidence that L2 may function in endosomal
escape of incoming virions (Kamper et al., 2006) and nuclear trafﬁc
of the viral genome (Day et al., 2004; Fay et al., 2004; Roden et al.,
2001).
L2 protein was found to interact with several host proteins includ-
ing actin (Yang et al., 2003), the microtubule-binding protein dynein
(Florin et al., 2006), and the endoplasmic reticulum t-snare Syntaxin-
18 (Laniosz et al., 2007).
Different mechanisms of endocytosis (involving either clathrin,
caveolin, or tetraspanin domains) have been proposed for different
papillomavirus types (Day et al., 2003; Sapp and Bienkowska-Haba,
2009; Smith et al., 2007, 2008; Spoden et al., 2008). The L2 minor
capsid protein enters the nucleus twice during the viral life cycle:
in the initial phase of infection when it accompanies the viral ge-
nome to the nucleus, and in the productive phase of infection
when together with L1 major capsid protein it is involved in encap-
sidation of the newly replicated viral DNA. Cleavage of L2 at a furin
consensus site located in the N-terminus was reported to be
414 S. Mamoor et al. / Virology 422 (2012) 413–424required during the initial stage of infection, although it is not
known what percent of the L2 molecules are processed by furin
(Richards et al., 2006). Recently, it has been shown that papillomavi-
rus infection also requires γ-secretase at a step after disassembly
of the virions in endosomes and before the entry of the L2-viral
genome complex into the nucleus (Karanam et al., 2010). The
target for the γ-secretase cleavage remains to be determined, and
potential candidates are either the L2 itself or an intracellular
receptor (Karanam et al., 2010). During the productive phase of
infection the expression and nuclear import of L2 in natural lesions
precede expression and nuclear translocation of L1 major capsid
protein (Florin et al., 2002). The L2 protein has a diffuse nuclear
localization in cervical intraepithelial neoplasia lesions and HPV16-
transduced organotypic cultures (Lin et al., 2009). We have previ-
ously determined that HPV16 L2 contains two nuclear localization
signals (NLSs), one at the amino-terminus (nNLS) and the other at
the carboxy-terminus (cNLS). Either NLS could mediate nuclear
import of a GST reporter in the in vitro nuclear import assays in
digitonin-permeabilized HeLa cells via interaction with speciﬁc kar-
yopherins (Darshan et al., 2004). We established that HPV16 L2
can interact with Kap α2β1 heterodimers, Kap β2 and Kap β3 nucle-
ar import receptors via its NLSs and enter the nucleus via multiple
pathways (Darshan et al., 2004). However, the transport signals con-
tributing to the nucleocytoplasmic trafﬁc of HPV16 L2 in vivo have
not been examined. In this study we performed a detailed in vivo
analysis of the nucleocytoplasmic transport signals of HPV16 L2
capsid protein using ﬂuorescent confocal microscopy analysis of dif-
ferent EGFP–16L2 fusions expressed in HeLa cells. We conﬁrmed
that the two NLSs previously characterized in vitro can function in-
dependently in vivo mediating the nuclear localization of HPV16 L2
protein. Moreover, we discovered that HPV16 L2 has an arginine-
rich nuclear retention signal (NRS) mediating its nuclear retention
and accumulation, and also a leucine-rich nuclear export signal
(NES) mediating its nuclear export in a CRM1-dependent manner.
Signiﬁcantly, mutations of critical residues in the NRS strongly re-
duced HPV16 infectivity in a murine challenge model and in HaCaT
cells. These data indicate that the nucleocytoplasmic trafﬁc of
HPV16 L2 is more complex than previously anticipated and it is me-
diated by multiple transport signals.
Results
Both the nNLS and cNLS of HPV16 L2 protein can function independently
in vivo
Previously we have established that the high risk HPV16 L2 minor
capsid protein has two NLSs that can interact with karyopherins/
importins and mediate the nuclear import of 16L2 in digitonin-
permeabilized HeLa cells in vitro (Darshan et al., 2004).
To investigate the localization of HPV16 L2 in HeLa cells we tran-
siently transfected HeLa cells with an EGFP–16L2 fusion plasmid
(EGFP fused at the N-terminus of 16L2) and analyzed the localiza-
tion of the translated EGFP–16L2. The transfected HeLa cells were
immunostained with the RG-1 mouse anti-L2 monoclonal antibody,
followed by a secondary anti-mouse IgG conjugated to Alexa Fluor
594. Analysis of both the EGFP ﬂuorescence and the 16L2 immunos-
taining using confocal ﬂuorescence microscopy revealed that the
EGFP–16L2 is nuclear in the majority of the cells (Figs. 1A and B).
In order to analyze the roles of the nNLS and cNLS in vivo we gener-
ated the following plasmid mutants: EGFP–16L2ΔN lacking the
nNLS, EGFP–16L2ΔC lacking the cNLS and the EGFP–16L2ΔNΔC lack-
ing both NLSs, and transiently transfected HeLa cells with these mu-
tant plasmids. Both the EGFP–16L2ΔN and the EGFP–16L2ΔC were
localized in the nucleus in the majority of cells like the EGFP–16L2
wild type, whereas the EGFP–16L2ΔNΔC double mutant had a cyto-
plasmic and pancellular localization (Figs. 1A and B). These datasuggest that both the nNLS and the cNLS can independently mediate
the nuclear localization of 16L2 minor capsid protein in vivo.
HPV16 L2 has a nuclear retention sequence rich in arginine residues
HPV16 L2 has a middle region rich in arginine residues
(296SRRTGIRYSRIGNKQTLRTRS316), which cannot mediate nuclear im-
port of a GST reporter in digitonin-permeabilized HeLa cells (Darshan
et al., 2004). To investigate if this arginine-rich region has any role
in the nuclear localization of 16L2 we generated several mutants:
EGFP–16L2ms1 (RR297EE), EGFP–16L2ms2 (RTR313EEE), and EGFP–
16L2ms3 (ms1 and ms2). These mutants retain both the cNLS and
nNLS, and contain glutamic acid substitutions in the arginine-rich
middle region. Confocal microscopy analysis of the localization of
these L2 middle region mutants in HeLa cells revealed that mutation
of either Arg pair affects the retention of EGFP–16L2 in the nucleus
(Fig. 2). Quantitative analysis revealed a mixed phenotype, with ei-
ther ms1 or ms2 mutation reducing the percent of cells with mostly
nuclear localization to ~30%, and the rest of the cells having pancellu-
lar or mostly cytoplasmic localization for EGFP–16L2ms1 and EGFP–
16L2ms2 (Fig. 3). The double mutant EGFP–16L2ms3 showed a simi-
lar reduction in nuclear localization and increase in pancellular and
mostly cytoplasmic localization, with no increase in the severity of
the nuclear retention defect in comparison with the ms1 and ms2
mutants (Fig. 3). Together, the data from these experiments indicate
that this arginine-rich sequence in the middle region of HPV16 L2
functions as a nuclear retention sequence (NRS) in vivo and the Arg
residues are critical for this function. Furthermore, the cytoplasmic
and pancellular localization of 16L2 nuclear retention mutants con-
taining both NLSs suggests an active export mechanism for 16L2, as
EGFP–16L2 is well above the limit for passive diffusion into the cyto-
plasm. Note that there is a larger variation between different experi-
ments for the L2 nuclear retention mutants regarding their percent of
cells with pancellular and cytoplasmic localization, further suggesting
that they shuttle between the nucleus and the cytoplasm. The same
ms1, ms2 andms3mutations in the context of EGFP–16L2ΔNΔC, lack-
ing both NLSs, completely changed the pancellular localization
that was still present in some 50% of cells to cytoplasm (Fig. 1B and
Fig. S1, A and B). This suggests that the 16L2 NRS may have some
very weak nuclear import activity.
HPV16 L2 protein can be exported out of the nucleus in a CRM1-
dependent manner
The fact that EGFP–16L2 nuclear retention mutants displayed a
mixed phenotype, with a majority of cells containing pancellular
and mostly cytoplasmic localization, suggested that these 16L2 nu-
clear retention mutants were being exported from the nucleus into
the cytoplasm via a signal-mediated pathway. A major nuclear ex-
port pathway is mediated by the CRM1 nuclear export receptor,
which mediates nuclear export of cargoes containing leucine-rich
NESs. To analyze if the CRM1 pathway is involved in the nuclear ex-
port of 16L2 nuclear retention mutants we used a speciﬁc chemical
inhibitor of CRM1, ratjadone A (RJA). RJA inhibition functions simi-
larly to Leptomycin B (LMB) inhibition, it covalently modiﬁes a cys-
teine residue in the NES-binding pocket of CRM1 resulting in
inhibition of NES-binding (Hutten and Kehlenbach, 2007; Meissner
et al., 2004). Twenty-one hours after transfection of HeLa cells
with EGFP–16L2ms1, EGFP–16L2ms2, or EGFP–16L2ms3, the cells
were treated with 10 ng/mL RJA for three and a half hours. After
the RJA treatment, the cells were ﬁxed, immunostained and
analyzed by confocal ﬂuorescence microscopy. As positive and
negative controls for the RJA drug treatment, we used the EGFP-
16E7-NESrev plasmid that contains the HPV16 E7 oncoprotein fused
to the strong leucine-rich NES of HIV-1 Rev, or EGFP alone,
Fig. 1. EGFP–16L2 is localized in the nucleus, and both the nNLS and cNLS of 16L2 can function independently in vivo. A. HeLa cells were ﬁxed 24 h after transfection with either
EGFP–16L2 (subpanels a, e and i), EGFP–16L2ΔN (subpanels b, f, and j), EGFP–16L2ΔC (subpanels c, g, and k), or EGFP–16L2ΔNΔC (subpanels d, h, and l), immunostained with
RG-1 monoclonal antibody against L2 (and a corresponding IgG conjugated to Alexa 594), and examined by confocal laser-scanning microscopy. Anti-L2 staining is shown in
the middle row (subpanels e, f, g, and h respectively), while DAPI (4ʼ, 6ʼ-diamidino-2-phenylindole) staining of the nuclei is shown in the bottom row (subpanels i, j, k and l, re-
spectively). B. Cells were phenotyped as having either mostly nuclear (black bars), pancellular (gray bars), or mostly cytoplasmic localization (striped bars) of EGFP–16L2 or EGFP–
16L2 mutants, and quantitative analysis is represented graphically with average and standard deviation.
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16E7-NESrev was cytoplasmic in a majority of cells transfected and
the RJA treatment resulted in a dramatic re-localization of the
EGFP-16E7-NESrev fusion protein into the nucleus in the majorityof cells (data not shown). The pancellular localization of EGFP was
not affected by the RJA treatment (data not shown). The RJA treat-
ment resulted in a signiﬁcant re-localization of the 16L2 nuclear
retention mutants to the nucleus (Fig. 3). The RJA treatment of
Fig. 2. Mutation of critical arginine residues in a middle sequence to glutamic acid affects the nuclear retention of HPV16 L2, in the presence of both NLSs. HeLa cells were trans-
fected with either EGFP–16L2 (panels A, E, and I), EGFP–16L2ms1 (panels B, F, and J), EGFP–16L2ms2 (panels C, G, and K), or EGFP–16L2ms3 (panels D, H, and L), ﬁxed after 24 h
and immunostained with RG-1 monoclonal antibody against L2 (and a corresponding IgG conjugated to Alexa 594), and then examined by confocal laser-scanning microscopy.
Anti-L2 staining is shown in the middle row (panels E, F, G, and H, respectively), while DAPI staining of the nuclei is shown in the bottom row (panels I, J, K, and L, respectively).
The percent of cells with a speciﬁc localization of EGFP–16L2 or mutants is also indicated on the panels.
Fig. 3. HPV16 L2 nuclear retention mutants re-localize to the nucleus in the presence of RJA, a speciﬁc inhibitor of CRM1 nuclear export receptor. Twenty-one hours post-transfec-
tion with either EGFP-L2, EGFP–16L2ms1, EGFP–16L2ms2, or EGFP–16L2ms3, HeLa cells were treated with either fresh DMEM or 10 ng/mL RJA for 3.5 h. After ﬁxation, cells were
immunostained with RG-1 monoclonal antibody against L2 (and a corresponding IgG conjugated to Alexa 594) and examined by confocal laser-scanning microscopy. Cells were
phenotyped as having either mostly nuclear (black bars), pancellular (gray bars), or mostly cytoplasmic (striped bars) localization of EGFP–16L2 or EGFP–16L2 mutants, and quan-
titative analysis is represented graphically with average and standard deviation.
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Fig. 4. Deletions in a potential cNES rescue the nuclear localization of the 16L2ms4 nuclear retention mutant. A. HeLa cells were ﬁxed 24 h after transfection with either EGFP–
16L2ms4 (subpanels a, d, and g), EGFP–16L2ms4t1 (subpanels b, e, and h) or EGFP–16L2ms4t2 (subpanels c, f, and i), immunostained with RG-1 monoclonal antibody against
L2 (and a corresponding IgG conjugated to Alexa 594), and examined by confocal microscopy. Anti-L2 staining is shown in the middle row (subpanels d, e, and f), while DAPI stain-
ing of the nuclei is shown in the bottom row (subpanels g, h, and i). B. Cells were phenotyped as having either mostly nuclear (black bars), pancellular (gray bars), or mostly
cytoplasmic localization (striped bars), and the quantitative analysis is represented graphically in B.
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crease to ~60% of the transfected cells having mostly nuclear locali-
zation and a concomitant decrease to 20% of cells having mostly
cytoplasmic localization (Fig. 3). The fact that the RJA treatment in-
duced re-localization of EGFP–16L2 nuclear retention mutants was
a strong indication that the 16L2 mutants were shuttling between
the nucleus and the cytoplasm. To eliminate the possibility that
the mutation (i.e. charge of glutamic acid) was leading to some par-
tial misfolding of the EGFP–16L2 nuclear retention mutants, we
also generated the EGFP–16L2ms4 (RR297AA) and EGFP–16L2ms5
(RTR313AAA) mutants. Analysis of their localization revealed a
mixed phenotype, with either ms4 and ms5 mutation reducing the
percent of cells with mostly nuclear localization to ~25%, and ~50%
respectively, with the rest of cells having a pancellular localization
(Figs. 4B and 5B).Fig. 5. Deletion of the cNES rescues the nuclear localization of the 16L2ms5 nuclear retenti
(subpanels a, b, and c), EGFP–16L2ms5t1 (subpanels d, e, and f), or EGFP–16L2ms5t2, immu
gated to Alexa 594), and examined by confocal microscopy. B. Cells were phenotyped as ha
localization (striped bars), and the quantitative analysis is represented graphically with avHPV16 L2 has a leucine-rich NES mediating its nuclear export in a CRM1-
dependent manner
The RJA results of partial re-localization of 16L2 nuclear retention
mutants suggest that 16L2 shuttles between the nucleus and the
cytoplasm, and that 16L2 exits the nucleus via a CRM1-dependent
pathway, either directly through its own NES or indirectly through
binding to an NES-containing cellular protein. Analysis of the HPV16
L2 sequence revealed the existence of two potential leucine-rich
NESs that match the NES consensus motif: one toward the N-
terminus (nNES: 51MGVFFGGLGI60) and the other at the C-terminus
(cNES: 462LPYFFSDVSL471), followed by only two alanine residues.
To investigate if the potential nNES is functional and can mediate
the nuclear export of 16L2 we generated the following nNES mutants
in the EGFP–16L2ms4 background: s1(FF54AA) and s2(LGI58AAA),on mutant. A. HeLa cells were ﬁxed 24 h after transfection with either EGFP–16L2ms5
nostained with RG-1 monoclonal antibody against L2 (and a corresponding IgG conju-
ving either mostly nuclear (black bars), pancellular (gray bars), or mostly cytoplasmic
erage and standard deviation.
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EGFP–16L2ms4s1 and 16L2ms4s2 mutant plasmids. Analysis of the
localization of these translated EGFP–16L2 mutants revealed similar
pancellular localizations for the EGFP–16L2ms4, EGFP–16L2ms4s1
and EGFP–16L2ms4s2 proteins in the majority of cells (Fig. S2, A
and B). These data suggest that this potential nNES is not a functional
NES involved in nuclear export of 16L2 minor capsid protein. This is
not surprising as this sequence is located in a highly hydrophobic
region of 16L2, which could be buried inside the molecule and not
exposed at the surface.
To investigate if the potential cNES (462LPYFFSDVSL471) functions
in nuclear export of 16L2 protein we generated the following two
cNES truncated mutants in the EGFP–16L2ms4 nuclear retention mu-
tant background: t1: 462L _(containing a stop codon at 463P), and t2:
462LPYFFSD_ (containing a stop codon at 469V). After transient
transfection of HeLa cells with these plasmids we examined the local-
ization of the expressed EGFP–16L2ms4, EGFP–16L2ms4t1, and
EGFP–16L2ms4t2 mutants using ﬂuorescence confocal microscopy.
Interestingly, both the t1 and t2 cNES deletion mutants had a mostly
nuclear localization in the majority of cells in contrast with the
pancellular localization of EGFP–16L2ms4 (Figs. 4A and B). These
data indicate that the t1 and t2 deletions in the cNES block nuclear
export and cause accumulation of the EGFP–16L2ms4 nuclear
retention mutant in the nucleus. Overall the data suggest that the
cNES (462LPYFFSDVSL471) functions in nuclear export of 16L2
minor capsid protein and that the 469V and 471L are essential
amino acids for the cNES export function.
We also generated t1 and t2 deletions in the 16L2ms5 nuclear
retention mutant and analyzed their localization in HeLa cells in com-
parison with the EGFP–16L2ms5. The EGFP–16L2ms5 had a mostly
nuclear localization in some 50% of cells and a pancellular localization
in the rest of the transfected cells (Figs. 5A and B). In contrast, the
EGFP–16L2ms5t1 and EGFP–16L2ms5t2 had a nuclear localization in
over 90% of cells (Figs. 5A and B). We obtained a similar rescue of
the nuclear localization to over 90% of transfected cells for the
EGFP–16L2ms3t1 mutant (Fig. S3). Overall, these data indicate that
deletions in the cNES rescue the nuclear localization of the 16L2ms5
and 16L2ms3 nuclear retention mutants, further suggesting that this
cNES functions in nuclear export of 16L2.
We next examined the roles of 462L, 465FF amino acids in the nu-
clear export function of 16L2's cNES by analyzing the localization of
EGFP–16L2ms4 L462A and EGFP–16L2ms4 FF465AA mutants in com-
parison with EGFP–16L2ms4 after transfection in HeLa cells. Both the
L462A and FF465AA mutations rescued the nuclear localization of the
EGFP–16L2ms4 nuclear retention mutant to over 90% of transfected
cells (Figs. 6A and B). These data conﬁrm that the cNES functions
in nuclear export of 16L2 and that the 462L, 465FF amino acids play a
critical role in the export function.
A scheme of all the nucleocytoplasmic transport signals of HPV16
L2 minor capsid protein, the nNLS, cNLS, the NRS in the middle of the
protein and the cNES located at the C-terminus of L2, is shown in
Fig. 7.Pseudovirions containing the 16L2 NRS mutants, RR297EE and RR297AA,
showed strongly reduced infectivity upon murine vaginal challenge and
in HaCaT cells
To investigate if the NRS and/or the NES play a role during the
HPV16 infection we generated HPV16 pseudoviruses containing ei-
ther wild type HPV16 L2, or L2 with mutations targeting either the
NRS or NES. Incorporation of these mutations targeting either the
NRS or NES did not adversely impact the yield of pseudovirus in the
peak fraction from the Optiprep gradient or the co-assembly of L1
with L2 as demonstrated by the L2 immunoblot of wild type and mu-
tant pseudoviruses (Fig. S4), and had limited effect upon the presenceof Benzonase-resistant luciferase reporter DNA as determined by Q-
PCR (Table 1). This suggests that neither the NRS nor the NES are crit-
ical for the assembly of the capsid and encapsidation of DNA and that
these minimal mutations do not cause structural defects in the capsid.
Therefore we sought to determine their role in the early events of in-
fection by examining the infectivity of each pseudovirion preparation
by vaginal challenge of mice as previously described (Roberts et al.,
2007). As negative control we used mice with passively transferred
HPV16 L1 VLP anti-serum 1 day prior to vaginal challenge. For both
NRS L2 mutants, RR297AA and RR297EE, the infectivity was strongly
reduced almost to the background level of the negative control
(Fig. 8). Since this effect cannot be accounted for by reduced pseudo-
virion assembly and L2 incorporation, these data clearly suggest that
the nuclear retention of HPV16 L2 mediated by its NRS is important
during the initial phase of viral infection. For the NES L2 mutant
FF465AA defective in nuclear export, the infectivity was signiﬁcantly
reduced to some 13% of the wild type (Fig. 8). Although less pro-
nounced, there was a reduction in infectivity for the NES L2 deletion
mutant V469_ to 42% of the wild type average level (Fig. 8).
We also performed infectivity assays in HaCaT cells with HPV16 L2
wild type andmutant pseudoviruses in the absence or presence of the
neutralizing RG1 antibody. The neutralization with the RG1 antibody
was used as a negative control. For both NRS L2 mutants, RR297AA
and RR297EE, the infectivity in HaCaT keratinocytes was strongly re-
duced to background levels of the negative control with the neutral-
izing RG1 antibody (Fig. 9). These data correlate with the in vivo
infectivity results in the mouse vaginal model, further supporting
that the nuclear retention of HPV16 L2 mediated by its NRS is critical
during the initial phase of viral infection. There was also a reduction
in infectivity in HaCaT cells with the two NES L2 mutants, FF465AA
and V469_, although less pronounced (Fig. 9), similarly with the
results obtained in the murine vaginal challenge model.
Discussion
Nuclear localization of L2 minor capsid protein is required for viral
genome localization to the nucleus during the initial phase of infec-
tion, and for genome encapsidation and assembly of infectious viral
progeny during the productive phase of infection (Day et al., 2004;
Fay et al., 2004; Florin et al., 2002; Holmgren et al., 2005).
In this study, we investigated the signals that dictate the nucleocy-
toplasmic transport of the HPV16 L2 minor capsid protein in living
HeLa cells using confocal microscopy analysis of the localization of
different expressed EGFP–16L2 mutants. Data from transient trans-
fections with EGFP–16L2 wild type and EGFP–16L2ΔN, ΔC, ΔNΔC de-
letion mutants indicated that both the cNLS and nNLS of 16L2 could
independently mediate the nuclear localization of 16L2 in vivo. This
is consistent with our previous biochemical data demonstrating that
16L2 has an nNLS and a cNLS, and either NLS can mediate nuclear im-
port of 16L2 in vitro in digitonin-permeabilized HeLa cells via interac-
tions with speciﬁc karyopherins (Darshan et al., 2004). The mostly
cytoplasmic localization in some 50% cells and pancellular localiza-
tion in the remaining 50% cells of the EGFP–16L2ΔNΔC lacking both
NLSs suggested that there is no additional strong NLS in the 16L2.
This is in agreement with our previous ﬁndings that showed that re-
combinant 16L2ΔNΔC could not be imported into the nuclei of
digitonin-permeabilized HeLa cells, and that a middle arginine-rich
region could not mediate nuclear import of a GST reporter in vitro
(Darshan et al., 2004). We have previously shown that the high risk
HPV18 L2 and the low risk HPV11 L2 have two similar NLSs
(Table 2), and that both the nNLS and the cNLS can function indepen-
dently in vivo in mediating the nuclear localization of these L2 pro-
teins via interactions with speciﬁc karyopherins (Bordeaux et al.,
2006; Klucevsek et al., 2006). Also, the low risk HPV6b L2 has both
an nNLS and a cNLS (Table 2), which can mediate the nuclear localiza-
tion of HPV6b L2 in vivo (Sun et al., 1995). Interestingly, BPV1 L2 has
Fig. 6. The effect of L462A and FF465AA mutations in the cNES on the localization of the 16L2ms4 nuclear retention mutant. HeLa cells were ﬁxed 24 h after transfection with either
EGFP–16L2ms4 (subpanels A, D, and G), EGFP–16L2ms4 L462A (subpanels b, e, and h) or EGFP–16L2ms4 FF465AA (subpanels c, f, and i), immunostained with RG-1 monoclonal
antibody against L2 (and a corresponding IgG conjugated to Alexa 594), and examined by confocal microscopy. Anti-L2 staining is shown in the middle row (subpanels d, e, and
f), while DAPI staining of the nuclei is shown in the bottom row (subpanels g, h, and i). B. Cells were phenotyped as having either mostly nuclear (black bars), pancellular (gray
bars), or mostly cytoplasmic localization (striped bars), and the quantitative analysis is represented graphically with average and standard deviation.
420 S. Mamoor et al. / Virology 422 (2012) 413–424two similar NLSs and deletion of either the nNLS or the cNLS inhibits
infectivity at a step after cell entry of BPV1 pseudovirions (Fay et al.,
2004; Roden et al., 2001).
Mutation of the arginine pairs 297RR and 313 RTR to either gluta-
mic acid or alanine affected the nuclear retention of 16L2 in the pres-
ence of both of its NLSs suggesting that this middle arginine-rich
sequence functions in the nuclear retention of 16L2 in vivo and that
these arginine residues are essential for the NRS function. A previous
study had suggested a possible role for this region in the nuclearretention of low risk HPV6b L2 minor capsid protein (Sun et al.,
1995). Signiﬁcantly, the 16L2's NRS is well conserved in other HPV
L2 proteins, including the high risk HPV types 18, 31 and 33 and the
low risk HPV types 6 and 11 (Table 3). It will be of interest to see if
the corresponding NRS sequence has a similar function in these L2
proteins of other HPV types. At this point we can only speculate on
the molecular mechanism(s) by which the NRS mediates retention
of 16L2 in the nucleus. The 16L2 protein could form a complex with
a nuclear protein(s) or could interact with the negatively charged
Fig. 8. The effect of mutations in the NRS and NES of 16L2 on HPV infection of the mu-
rine vaginal tract. Wild type and L2 mutant pseudoviruses were applied intravaginally
in each mouse (5 mice per group) and after 72 h the mice were anesthetized, luciferin
was deposited intravaginally and the images were recorded with a Xenogen IVIS 200.
The raw data were computed using Living Image software (Caliper Life Sciences) and
the bioluminescence data are plotted for each group.
Fig. 7. A scheme of the nucleocytoplasmic transport signals of HPV16 L2 minor capsid
protein.
421S. Mamoor et al. / Virology 422 (2012) 413–424phosphate groups of the DNA backbone via the positively charged ar-
ginine residues. Although we have previously shown that the NRS of
HPV16 L2 can bind promiscuously to DNA in vitro (Klucevsek et al.,
2006), it is not known whether this NRS binds the viral genome in
vivo. Signiﬁcantly, analysis of HPV16 infectivity in a murine challenge
model and in HaCaT human keratinocytes using pseudovirions with
16L2 mutants containing mutations in the NRS (RR297AA and
RR297EE) that inhibit 16L2 nuclear retention, revealed a strong inhi-
bition of infectivity almost to the background level. These data clearly
suggest that the nuclear retention of HPV16 L2 mediated by its NRS is
critical during the initial phase of HPV16 infection in vivo. It would be
of great interest to determine in the future the exact step during in-
fection that is affected by a defective L2's NRS. One possibility is
that this NRS of 16L2 might be involved in the nuclear retention of
the L2-viral genome complex during the initial phase of HPV infec-
tion. Mapping studies by Becker et al. (2003) suggest that this NRS
is not involved in binding to ND-10, an interaction that potentiates in-
fection and requires PML (Day et al., 2004). It is noteworthy that L2
also interacts with numerous other nuclear proteins deﬁned by
yeast 2-hybrid studies and co-localization, including PATZ and
PLINP (Gornemann et al., 2002), but their relationship to the NRS
and infection remains to be determined.
The results showing that the RJA nuclear export inhibitor causes par-
tial re-localization of 16L2 nuclear retention mutants into the nucleus
indicated that 16L2 could also exit the nucleus via a CRM1-dependent
export pathway. Indeed, motif analysis followed by mutagenesis-
localization investigation revealed that 16L2 contains also a leucine-
rich cNES (462LPYFFSDVSL471), which can mediate nuclear export of
16L2 in a CRM1-dependent manner. The 462L and 465FF residues were
essential for the cNES export function, as their mutagenesis to alanine
inhibited nuclear export and as a consequence rescued the nuclear lo-
calization of the 16L2 nuclear retention mutants. Signiﬁcantly, this
cNES of 16L2 is well conserved in other L2 proteins of high risk types
31 and 33 and partially conserved in the L2 proteins of low risk HPV
types 6 and 11 (Table 3). It will be interesting to determine if the corre-
sponding NES sequences function in nuclear export for other HPV types.
A previous study showed that HPV16 pseudovirions containing a C-
terminally truncated 16L2 mutant, 1–464, with partially deleted cNES
(462LPY_) had only 16% infectivity in comparison with the wild type
16L2 after 72 h post-infection in 293TT cells (Florin et al., 2006). Our
in vivo analysis of HPV16 infection of the murine vaginal tract with
pseudoviruses containing L2 NES mutants defective in L2 nuclear
export, revealed that both mutations reduced infectivity, although lessTable 1
Effect of mutations in the NRS and NES of HPV16 L2 on reporter DNA
encapsidation.
HPV16 L2 status % DNA packing vs. WT
WT 100
RR297EE 86
RR297AA 35
FF465AA 49
V469_ 144pronounced than the NRS mutations (to 13% of wild type for the
FF465AA mutant and to 42% of wild type for the V469_ mutant).
There was also some reduction of infectivity with these 2 NES L2
mutants in HaCaT cells, again less pronounced than for the NRS
mutants. Between these two L2 NES mutations, the FF465AA mutation
had a slightly stronger inhibitory activity on nuclear export and
consequently rescued the nuclear localization of the 16L2ms4 NRS
mutant to wild type levels at 92±5.4% (Fig. 6B) in comparison with
the V469_ deletion mutation that rescued the nuclear localization to
83.7±7.5% (Fig. 4B).
The cNES of 16L2 partially overlaps with the dynein-binding
domain mapped to the C-terminal 40 amino acids of 16L2 and the
dynein–L2 interaction is required for infectivity (Florin et al., 2006).
As the dynein-binding domain partially overlaps with the cNES we
cannot exclude the possibility that the 16L2 FF465AA mutation may
also affect dynein binding. Consequently, the reduction in infectivity
with the L2 FF465AA mutant pseudovirus could be due to reduced
dynein binding to L2 and to a defective NES.
The discovery that the 16L2 minor capsid protein has a leucine-
rich NES that can mediate its nuclear export in a CRM1-dependentFig. 9. The effect of mutations in the NRS and NES of 16L2 on HPV infectivity in HaCaT
cells. HaCaT cells were incubated for 72 h with equal amounts of HPV16 L2 wild type
and mutant pseudoviruses with and without RG1 antibody speciﬁc to HPV16 L2. The
luciferase activity in cell lysate was determined with a luciferase assay kit and the bio-
luminescence was measured with a Luminometer.
Table 2
Comparison of the nNLS and cNLS of HPV16 L2 with other L2 proteins of high and low
risk HPV types.
HPV type nNLS cNLS
HPV16 L2 MRHKRSAKRTKR RKRRKR
HPV18 L2 MVSHRAARRKR KKRKR
HPV33 L2 MRHKRSTRRKR RRRRKR
HPV11 L2 MKPRARRRKR RRRRKR
HPV6b L2 MAHSRARRRKR RKRRKR
The basic amino acids K and R characteristic of these NLSs are in bold.
422 S. Mamoor et al. / Virology 422 (2012) 413–424manner raises the question of why the L2 minor capsid protein that
has nuclear localization and essential nuclear functions during the
viral cycle needs to actively exit the nucleus. One possibility would
be that L2 nuclear export could regulate the quantity of L2 in
the nucleus allowing only as much L2 as required for genome
encapsidation during the productive phase of infection. As L2 also
has a membrane-penetrating function and cytotoxic properties via
its C-terminus (Kamper et al., 2006), regulating the concentration of
L2 in the nucleus would protect the host cell from premature virus-
induced nuclear damage, which would be detrimental to viral propa-
gation. Another possibility would be that the interaction of the
leucine-rich cNES of 16L2 with CRM1 nuclear export receptor might
facilitate the nuclear entry of the viral genome. Future detailed stud-
ies would be necessary to determine the step in the viral cycle affect-
ed by a defective L2's NES and the potential role of 16L2 nuclear
export during HPV infection.
In conclusion, in this study we determined that HPV16 L2 minor
capsid protein has several transport signals mediating its nucleocyto-
plasmic trafﬁc in vivo: two NLSs at the N- and C-termini that can
independently mediate nuclear import of L2, an arginine-rich NRS
in the middle of the protein involved in its nuclear retention and a
leucine-rich NES at the C-terminus mediating its nuclear export.
Materials and methods
Generation of EGFP fusion plasmids with HPV16 L2 wild type and
mutagenesis
The pEGFPc1 vector (Clontech) was used to express 16L2 in HeLa
cells. EGFP–16L2 was constructed as follows: pEGFPc1 was prepared
for ligation by double digestion with EcoRI and BamHI at 37 °C for
1 h, and the linearized vector was selectively puriﬁed by agarose gel
electrophoresis (Qiagen). The HPV16 L2 ORF (1.4 kb) was ampliﬁed
by the polymerase chain reaction (PCR) with oligonucleotide primers
incorporating ﬂanking EcoRI (forward) and BamHI (reverse) cloning
sites, in a reaction containing Platinum Pfx DNA Polymerase. The
PCR product was puriﬁed and then double digested with BamHI and
EcoRI for 1 h at 37 °C. The digested vector and PCR product were ligat-
ed with T4 DNA ligase (NEB). EGFP-L2ΔN was constructed as EGFP-
L2, but with the forward primer omitting the residues 1–12.
Site-directed mutagenesis was performed using the QuikChange™
Site-Directed Mutagenesis Kit from Stratagene with EGFP–16L2 as aTable 3
Comparison of the NRS and NES of HPV16 L2 with other L2 proteins of high and low
risk HPV types.
HPV type NRS NES
HPV16 L2 SRRTGIRYSRIGNKQTLRTRS LPYFFSDVSL
HPV18 L2 SRRGTVRFSRLGQRATMFTRS VPYFFADGFV
HPV31 L2 SRRNTVRYSRLGNKQTLRTRS VSYFFTDVSV
HPV33 L2 SRRHTVRFSRVGQKATLKTRS FPYFFTDVRV
HPV11 L2 SRRGLVRFSRIGQRGSMYTRS IPLFFSDVAA
HPV6b L2 SRRGLVRYSRIGQRGSMHTRS IPLFFTDVAA
The R and K residues in the NRS and the characteristic hydrophobic residues in the NES
are in bold.template together with corresponding overlapping mutated primers.
The deletion mutant EGFP-L2ΔC was generated using deletion
primers that omitted residues 456–461 of 16L2 using EGFP-L2
as a template. EGFP-L2ΔNΔC was generated as EGFP-L2ΔC but
with EGFP-L2ΔN as a template. The EGFP–16L2ms1(RR297EE),
EGFP–16L2ms2(RTR313EEE), EGFP–16L2ms3(RR297EE, RTR313EEE),
EGFP–16L2ms4(RR297AA) and EGFP–16L2ms5 (RTR313AAA) plas-
mids were generated using QuikChange™ Site-Directed Mutagenesis
with EGFP–16L2 as a template together with the corresponding over-
lapping mutated primers in the NRS region. Additional mutations in
the potential NESs were generated using EGFP–16L2ms4 as template:
1) in the potential nNES: s1: FF54AA and s2: LGI58AAA, and 2) in
the potential cNES: t1: 462L_ (containing a stop codon at 463P), t2:
462LPYFFSD_ (containing a stop codon at 469V), and two substitutions,
L462A and FF465AA. T1 and t2 deletion mutations of the cNES were
also generated using the EGFP–16L2ms5 as template.
All the resulting plasmidswere used to transformXL1-Blue cells and
the puriﬁed plasmids were conﬁrmed by sequencing (Euroﬁns MWG).
After conﬁrmation of mutagenesis, the entire L2 ORF of every mutant
was sequenced to conﬁrm the absence of spurious mutations.
Transfections assays and confocal ﬂuorescence microscopy
Transient transfections of HeLa cells (ATCC) with the correspond-
ing EGFP fusion plasmids (as indicated in the ﬁgure legends) were
performed using the lipid-based FuGENE6 mammalian transfection
reagent (Roche). HeLa cells were cultured onto poly-L-lysine
(Sigma) coated glass coverslips 24–36 h prior to transfection, at
70–80% conﬂuency in 24-well tissue culture plates. At 24 h post-
transfection, cells were washed in cold PBS and ﬁxed for 3 min in
100% methanol at −20 °C. Cells were washed in PBS and either
mounted onto glass sides for microscopy using Vectashield mounting
medium (Vector Laboratories) with 4,6,-diamidinophenylindole
(DAPI) to stain the nuclear DNA, or blocked for 1 h in 3% bovine
serum albumin (BSA) in PBS and immunostained with RG-1
mouse monoclonal antibody against residues 17–36 of HPV16 L2
(Gambhira et al., 2007) followed by a corresponding secondary anti-
body conjugated to Alexa Fluor 594. Ratjadone A (RJA), a speciﬁc
inhibitor of CRM1 nuclear export receptor, was used in drug treat-
ments of transfected cells. At 22 h post-transfection, HeLa cells were
treated with 10 ng/mL RJA in DMEM+ for 3.5 h. After treatment,
cells were ﬁxed and prepared as above.
Digital images were acquired on a Leica TCS Sp5 confocal micro-
scope. Quantitation of localization was performed when phenotypes
were complex, and classiﬁed as mostly nuclear, mostly cytoplasmic,
or pancellular (both in the nucleus and in the cytoplasm with no spe-
ciﬁc accumulation). Most quantitations were performed on the RG-1/
Alexa 594 immunostaining; some quantitations were performed on
the GFP ﬂuorescence. The statistical analysis of the quantitations
was presented graphically with average and standard deviation.
Immunoblot analysis of whole cell lysates of the transfected cells
with EGFP-L2 wild type and different mutants with GFP Ab revealed
the presence of the intact EGFP-L2 proteins and also of some free
EGFP; the western blots with the RG-1 Ab to L2 detected only the
intact EGFP-L2 wild type and the different EGFP-L2 mutants, and as
expected did not cross-react with the free EGFP.
Pseudovirus preparation
HPV16 pseudovirions with encapsulated luciferase reporter were
generated by cotransfection of 293TT cells with plasmids encoding
codon-modiﬁed L1 and wild type L2, L2 mutants RR297EE,
RR297AA, FF465AA, and V469_, respectively and a ﬁreﬂy luciferase
reporter plasmid, as described previously (Pastrana et al., 2004).
Cells collected after transfection were matured overnight in Brij 58
(0.5%) and benzonase (0.5%) and pseudovirions were puriﬁed by
423S. Mamoor et al. / Virology 422 (2012) 413–424centrifugation on an OptiPrep step gradient (27, 33, and 39%) at
40,000 rpm for 15 h. The DNA encapsidation for the different pseudo-
viruses was measured using real-time PCR.
Real-time PCR measurement of encapsidated luciferase reporter DNA
Reporter plasmid DNA containing ﬁreﬂy luciferase was puriﬁed
from 20 μl of each HPV pseudovirus samples using PureLink Viral
RNA/DNA Kits (Invitrogen). The real-time PCR reactions were con-
ducted using a total volume of 50 μl, containing 25 μl of TaqMan Uni-
versal PCR Master Mix (Applied Biosystems), 900 nM of forward and
reverse primers (TTG ACC GCC TGA AGT CTC TGA and ACA CCT GCG
TCG AAG ATG TTG), 250 nM of TaqMan probe (6FAM-CCG CTG AAT
TGG AAT CCA TCT TGC TC-TAMRA), and 5 μl of puriﬁed reporter
plasmid template using an iCycler IQ (Biorad). Each sample was per-
formed in triplicate. The real-time PCR thermal cycling conditions in-
cluded AmpliTaq Gold Activation at 95 °C for 10 min, followed by
40 cycles of the PCR step at 95 °C for 15 s and 60 °C for 1 min. FAM
ﬂuorescent emission (530 nm wavelength) was measured at the
end of the anneal/Extend step. The speciﬁcity of each reaction was
veriﬁed after completion of the protocol by melt curve analysis.
The amount of standard template plasmid was from 50 ng to
0.05 pg.
In vivo pseudovirus delivery and infection
Female Balb/c (6–8 weeks old) were purchased from the National
Cancer Institute (Frederick, MD, USA) and kept in the animal facility
of the Johns Hopkins School of Medicine (Baltimore, MD, USA).
Mouse experiments were approved by the Johns Hopkins University
Animal Care and Use Committee. All animal procedures were per-
formed according to approved protocols and in accordance with the
recommendations for the proper use and care of laboratory animals.
The mice received 3 mg of Depo-provera (Pﬁzer) 4 days prior to in-
fection as described (Roberts et al., 2007). Animals were infected
under anesthesia with a 25 μg PsV inoculum of 20 μl mixed with
20 μl of a 3% CMC preparation. The inoculum was delivered in two
doses, 20 μl before and 20 μl after Cytobrush treatment, using an
M20 positive-displacement pipette. Mice underwent a procedure in
conjunction with pseudovirus inoculation in which a Cytobrush cell
collector was inserted in the vagina and twirled clockwise and coun-
terclockwise 10 times. The material was delivered with an M20
positive-displacement pipette (Gilson), and standard dissecting for-
ceps were used to occlude the vaginal introitus to achieve maximal
retention of the material. For those mice receiving the passively
transferred L1 anti-serum, serum (30 μl) was diluted in 1× PBS to a
ﬁnal volume of 100 μl and was administered intraperitoneally 24 h
prior to infection. Infection was measured 72 h after pseudovirus de-
livery as previously described (Roberts et al., 2007). The raw data
were computed using Living Image software (Caliper Life Sciences).
An identical region of interest (ROI) was drawn around the luciferase
signal emitted from each mouse, and the average radiance within the
ROI was determined.
HPV infectivity assays in HaCaT cells
HPV16 pseudovirus infectivity and neutralization assays were car-
ried out as outlined previously (Jagu et al., 2009) in HaCaT cells (a
spontaneously immortalized human keratinocyte line). Brieﬂy,
HaCaT cells were seeded at 15,000 cells/well in 96-wells plate 24 h
prior to the assay. The wild type and mutant pseudoviruses were nor-
malized by L1 protein concentration and ~2.87×104 particles were
incubated with HaCaT cells for 72 h with and without RG1 antibody
speciﬁc to HPV16 L2 at 0.72 μg concentration. The luciferase activity
in the cell lysate was determined with a luciferase assay kit (Promega,
Madison, WI) according to the manufacturer's instructions. Thebioluminescence was measured with a Luminometer (Promega
Glomax Multidetection system, Promega, Madison, WI, USA).
Supplementary materials related to this article can be found on-
line at doi:10.1016/j.virol.2011.11.007.Acknowledgments
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